München
22.06.26 | 08:09
0,086 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Diamyd Medical AB (publ): Diamyd Medical announces update regarding interim CFO | 107 | GlobeNewswire (Europe) | Diamyd Medical today announces that Anna Styrud, appointed interim CFO in Diamyd Medical, will not be able to start her position as previously communicated due to changes in her availability. A review... ► Artikel lesen | |
| DIAMYD MEDICAL Aktie jetzt für 0€ handeln | |||||
| 11.06. | Diamyd Medical AB (publ): Diamyd Medical receives Notice of Allowance for Key Precision Medicine Patent | 128 | GlobeNewswire (Europe) | Diamyd Medical has been given notice that the USPTO has allowed a patent application and is expected to proceed to grant a patent protecting the use of retogatein (GAD65) to treat individuals with type... ► Artikel lesen | |
| 05.06. | Diamyd Medical AB (publ): Diamyd Medical provides update on ongoing Activities | 141 | GlobeNewswire (Europe) | Diamyd Medical today announced that it, as part of an ongoing strategic review, has received several proposals from external parties, including formal non-binding Letters of Intent, as well as invitations... ► Artikel lesen | |
| 22.05. | Diamyd Medical AB (publ): Diamyd Medical announces that Niklas Axelsson has decided to leave his position as CFO to take on a new role in another company | 164 | GlobeNewswire (Europe) | A review to find a successor will now begin, and Niklas will remain with the company for some time to enable a handover to this person.
"Although Niklas has worked for Diamyd for a relatively short... ► Artikel lesen | |
| 20.05. | Diamyd Medical AB (publ): Diamyd Medical receives GMP certification and manufacturing authorization for biological investigational medicinal products for human use | 230 | GlobeNewswire (Europe) | Diamyd Medical today announced a significant advancement in the company's operations related to the manufacturing of biological medicines (biologics). The company has now received GMP (Good Manufacturing... ► Artikel lesen | |
| 11.05. | Diamyd Medical AB (publ): Diamyd Medical provides an update on strategic review and financial position | 289 | GlobeNewswire (Europe) | Diamyd Medical today announces that the initial phase of the strategic review, initiated following the discontinuation of the Phase 3 DIAGNODE-3 trial, has been completed.
Strategic review update
The... ► Artikel lesen | |
| 24.04. | Diamyd Medical AB (publ): Diamyd Medical announces governance and leadership update | 244 | GlobeNewswire (Europe) | Further to the Company's press release regarding governance changes following the March 27 interim analysis of its DIAGNODE-3 study, Diamyd Medical today announces that Chairman Anders Essen-Möller... ► Artikel lesen | |
| 23.04. | Diamyd Medical AB (publ): Diamyd Medical announces governance and leadership changes | 236 | GlobeNewswire (Europe) | Following Diamyd Medical's unexpectedly negative results from the March 27 interim analysis of its DIAGNODE-3 study, the Board of Directors has implemented governance changes to strengthen oversight... ► Artikel lesen | |
| 10.04. | Diamyd Medical AB (publ): Diamyd Medical discontinues DIAGNODE-3 following evaluation confirming futility; initiates strategic review | 540 | GlobeNewswire (Europe) | Diamyd Medical today announced that it will discontinue the Phase 3 DIAGNODE-3 trial evaluating retogatein (rhGAD65) in Stage 3 type 1 diabetes. Following the previously reported interim analysis and... ► Artikel lesen | |
| 08.04. | Diamyd Medical AB (publ): Bulletin from Diamyd Medical's Extraordinary General Meeting 2026 | 392 | GlobeNewswire (Europe) | An Extraordinary general meeting of Diamyd Medical Aktiebolag (the "Company") was held on April 8, 2026.
The Extraordinary General Meeting resolved to approve the board of directors' resolution from... ► Artikel lesen | |
| 29.03. | Diamyd Medical AB (publ): Diamyd Medical updates on the interim efficacy analysis of Phase 3 DIAGNODE-3 trial | 404 | GlobeNewswire (Europe) | Diamyd Medical on Friday March 27th announced that the pre-specified interim efficacy analysis on 174 out of 321 participants of the ongoing Phase 3 DIAGNODE-3 trial yielded results that were unexpected... ► Artikel lesen | |
| 27.03. | Diamyd Medical AB: Diamyd Medical reports negative interim results of Phase 3 DIAGNODE-3 trial | 464 | GlobeNewswire (Europe) | Diamyd Medical today announced the completion of a pre-specified interim efficacy analysis on C-peptide in the ongoing pivotal Phase 3 DIAGNODE-3 trial evaluating retogatein (rhGAD65) in individuals... ► Artikel lesen | |
| 25.03. | Diamyd Medical AB: Quarterly Report 2 25/26 | 357 | GlobeNewswire (Europe) | September 2025 - February 2026, Diamyd Medical AB (publ), Fiscal year 2025/2026
Precision Medicine for type 1 diabetes
Fully enrolled registrational Phase 3 program
Diamyd Medical develops a... ► Artikel lesen | |
| 23.03. | Diamyd Medical AB: Notice Of Extraordinary General Meeting In Diamyd Medical Aktiebolag | 6 | Cision News | ||
| 23.03. | Diamyd Medical AB: Diamyd Medical enters into equity financing agreements with new U.S. sector specialist investors for up to USD 125 million and announces full enrollment in Phase 3 trial | 564 | PR Newswire | NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, ISRAEL, JAPAN, NEW ZEALAND... ► Artikel lesen | |
| 19.03. | Diamyd Medical AB: Diamyd Medical receives Notice of Grant in Japan for insulin-based antigen therapy patent in type 1 diabetes | 258 | GlobeNewswire (Europe) | Diamyd Medical has received a Notice of Grant in Japan for a patent covering the use of insulin-based antigens to treat individuals with type 1 diabetes who carry the HLA DR4-DQ8 genetic marker. Once... ► Artikel lesen | |
| 02.03. | DIAMYD MEDICAL AB: American Diabetes Association 86th Scientific Sessions to feature retogatein Phase 3 trial in dedicated symposium | 3 | Cision News | ||
| 24.02. | Diabetes-Studie: Diamyd Medical schließt Datenbank für Phase-3-Meilenstein ab | 6 | Investing.com Deutsch | ||
| 24.02. | Diamyd Medical completes database for phase 3 diabetes trial | 2 | Investing.com | ||
| 24.02. | Diamyd Medical AB: Diamyd Medical announces finalization of database for interim analysis in Phase 3 DIAGNODE-3 trial | 624 | GlobeNewswire (Europe) | The clinical database has been finalized for the pre-specified interim efficacy analysis in Diamyd Medical's ongoing pivotal Phase 3 trial (DIAGNODE-3) evaluating retogatein (rhGAD65) in individuals... ► Artikel lesen |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 38,010 | +2,31 % | EQS-PVR: Bayer Aktiengesellschaft: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Bayer Aktiengesellschaft
Bayer Aktiengesellschaft: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
15.06.2026... ► Artikel lesen | |
| NOVO NORDISK | 40,330 | +3,41 % | Novo Nordisk: Das sieht jetzt gar nicht mal so schlecht aus! | Die Aktie von Novo Nordisk handelte in den vergangenen Wochen unauffällig. Geschadet hat ihr das nicht, wie ein erfolgreicher Test der 50-Tage-Linie zeigt. Novo Nordisk schaut dem Markt noch immer hinterher... ► Artikel lesen | |
| PFIZER | 21,960 | -0,95 % | Pfizer-Finanzchef geht im August | NEW YORK (dpa-AFX) - Pfizer steht vor einem Wechsel im Finanzressort. Wie der US-Pharmakonzern am Donnerstag in New York mitteilte, wird Finanzvorstand Dave Denton sein Amt zum 15. August niederlegen... ► Artikel lesen | |
| ABBVIE | 201,70 | +5,91 % | AbbVie-Aktie: Neue Chancen nach Mega-Blockbuster Humira | Der Pharmakonzern AbbVie hält Kurs auf weiteres Wachstum und treibt die Expansion seiner wichtigsten Produkte konsequent voran. Besonders die Blockbuster Skyrizi und Rinvoq gewinnen zunehmend an Bedeutung... ► Artikel lesen | |
| ROCHE | 344,68 | +0,19 % | Roche Reports FDA Filing Acceptance For Lunsumio VELO, Polivy Combination | SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY, RO.SW, ROG.SW) announced the FDA has accepted the company's supplemental Biologics License Application for Lunsumio VELO, as a subcutaneous formulation... ► Artikel lesen | |
| MERCK & CO | 99,96 | +0,15 % | Dividendenbekanntmachungen (15.06.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A&W FOOD SERVICES OF CANADA INC CA0002251027 0,48 CAD 0,2966 EUR AEGON LTD ADR US0076CA1045 0,2468 USD 0,2134 EUR AGROB IMMOBILIEN... ► Artikel lesen | |
| ABBOTT LABORATORIES | 76,68 | -0,80 % | KI-Machtkampf: Google verliert Gemini-Kopf an OpenAI: Ist das der neue KI-Schock? | © Foto: Dominika Zarzycka - NurPhotoEin Topmanager hinter Googles Gemini-Modellen wechselt ausgerechnet zu OpenAI. Für Google kommt der Abgang zu einem heiklen Zeitpunkt - und zeigt, worum der härteste... ► Artikel lesen | |
| DERMAPHARM | 46,400 | -2,32 % | Lieferfähigkeit sichern: Dermapharm übernimmt Wobenzym | ||
| ZOETIS | 67,28 | -2,41 % | Zoetis (ZTS) Lost 22% in a Day; What Has Wall Street Worried? | ||
| DOCMORRIS | 8,595 | -1,43 % | Rebound-Alarm: Redcare-Aktie liefert zweistelliges Kursplus: Das ist der Grund | © Foto: Sheldon Cooper - SOPA Images via ZUMA Press WireDIe Online-Apotheke legt überraschend starke Zahlen vor und schraubt die Prognose hoch. Die Aktie startet durch und holt ihre Verluste des laufenden... ► Artikel lesen | |
| EYEPOINT | 11,900 | +0,85 % | EyePoint Aktionäre genehmigen Incentive-Plan und wählen Direktoren | ||
| PENTIXAPHARM | 2,050 | -7,24 % | PENTIXAPHARM HOLDING AG: Struktur im Stillstand | ||
| AXSOME THERAPEUTICS | 217,80 | -0,05 % | TD Cowen raises Axsome Therapeutics price target on Auvelity growth | ||
| DAIICHI SANKYO | 13,708 | -0,98 % | Daiichi Properties clinches awards for BGC portfolio | ||
| TRULIEVE CANNABIS | 8,050 | -3,94 % | Trulieve's NYSE Listing Is Historic. But Is the Stock Still Worth Buying? |
Das Unternehmen DIAMYD MEDICAL AB kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,086 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DIAMYD MEDICAL AB finden Sie auf Wallstreet Online.